AU2001294541A1 - Mammalian genes; related reagents and methods - Google Patents

Mammalian genes; related reagents and methods

Info

Publication number
AU2001294541A1
AU2001294541A1 AU2001294541A AU9454101A AU2001294541A1 AU 2001294541 A1 AU2001294541 A1 AU 2001294541A1 AU 2001294541 A AU2001294541 A AU 2001294541A AU 9454101 A AU9454101 A AU 9454101A AU 2001294541 A1 AU2001294541 A1 AU 2001294541A1
Authority
AU
Australia
Prior art keywords
methods
mammalian genes
related reagents
genes
reagents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294541A
Inventor
Naoko Arai
Daniel M. Gorman
Jeffery Grein
Hirokazu Kurata
Jeanine D. Mattson
Terrill K. Mcclanahan
Erin E. Murphy
Christi L. Parham
Theodore R. Sana
Chetan Savkoor
Kathleen M. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2001294541A1 publication Critical patent/AU2001294541A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Abstract

Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
AU2001294541A 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods Abandoned AU2001294541A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23126700P 2000-09-08 2000-09-08
US60/231,267 2000-09-08
PCT/US2001/028013 WO2002020569A2 (en) 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods

Publications (1)

Publication Number Publication Date
AU2001294541A1 true AU2001294541A1 (en) 2002-03-22

Family

ID=22868480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294541A Abandoned AU2001294541A1 (en) 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods

Country Status (9)

Country Link
US (6) US7060800B2 (en)
EP (2) EP2298789B1 (en)
JP (2) JP2004509617A (en)
CN (1) CN1452633A (en)
AT (1) ATE549347T1 (en)
AU (1) AU2001294541A1 (en)
CA (1) CA2419979A1 (en)
MX (1) MXPA03002049A (en)
WO (1) WO2002020569A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388019A1 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
WO2001040467A1 (en) 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
AU2001290524A1 (en) 2000-08-08 2002-02-18 Zymogenetics Inc. Soluble zcytor 11 cytokine receptors
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
WO2002016598A2 (en) * 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
JP2004509617A (en) * 2000-09-08 2004-04-02 シェーリング　コーポレイション Mammalian genes; related reagents and methods
EP1339847A2 (en) * 2000-11-28 2003-09-03 Amgen, Inc. Transforming growth factor-beta-related molecules and uses thereof
US20030027253A1 (en) * 2000-11-28 2003-02-06 Presnell Scott R. Cytokine receptor zcytor19
US20030099608A1 (en) 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
CA2462687A1 (en) * 2001-10-02 2003-04-17 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
IL164181A0 (en) 2002-03-22 2005-12-18 Zymogenetics Inc Anti-il-tif antibodies and methods of using in inflammation
US20040029228A1 (en) * 2002-04-19 2004-02-12 Presnell Scott R. Cytokine receptor
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
AU2003286624B2 (en) 2002-10-23 2008-11-13 Bristol-Myers Squibb Company Methods for treating viral infection using IL-28 and IL-29
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
JP2007524361A (en) * 2003-02-10 2007-08-30 アジェンシス， インコーポレイテッド 158P1D7 nucleic acid and corresponding protein useful for the treatment and detection of bladder cancer and other cancers
DE602004028347D1 (en) 2003-03-24 2010-09-09 Zymogenetics Inc ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND USE METHODS OF INFLAMMATION
PT2251353E (en) 2003-08-07 2013-05-07 Zymogenetics Inc Homogeneous preparations of il-29
EP1663281B1 (en) * 2003-08-29 2013-12-25 Dyax Corp. Poly-pegylated protease inhibitors
GB0325038D0 (en) 2003-10-27 2003-12-03 Ares Trading Sa Protein
WO2005097165A2 (en) 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1793845A2 (en) 2004-07-29 2007-06-13 ZymoGenetics, Inc. Use of il-28 and il-29 to treat cancer
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
GB0423973D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa C1q related points
JP2008539194A (en) * 2005-04-26 2008-11-13 ラボラトワール セローノ ソシエテ アノニム New treatment and / or prevention of cancer and / or arthritis
US20070020227A1 (en) 2005-07-20 2007-01-25 Sheppard Paul O Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP2010523695A (en) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド Use of inhibitors of TNFα and antihistamines to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
KR20170100071A (en) 2007-09-28 2017-09-01 포톨라 파마슈티컬스, 인코포레이티드 ANTIDOTES FOR FACTOR Xa INHIBITORS AND METHODS OF USING THE SAME
ES2607935T3 (en) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and procedures for their use
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
MX2012003693A (en) * 2009-10-01 2012-04-19 Alcon Res Ltd Olopatadine compositions and uses thereof.
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
CA2867444C (en) 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AR092219A1 (en) 2012-08-23 2015-04-08 Seattle Genetics Inc ANTIBODY-FARMACO (ADC) CONJUGATES THAT JOIN PROTEINS 158P1D7
WO2014075788A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015132672A2 (en) 2014-03-07 2015-09-11 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
EP3565834A1 (en) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3565589A1 (en) 2017-01-04 2019-11-13 Research Institute at Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN110229226B (en) * 2019-05-23 2023-04-11 西安医学院 SLFN11 truncated peptide and application and pharmaceutical composition thereof
BR112021026890A2 (en) 2019-07-08 2022-03-15 Res Inst Nationwide Childrens Hospital Antibody compositions to disrupt biofilms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88426A (en) 1869-03-30 Improved velocipede
US2736896A (en) 1951-12-04 1956-02-28 Sperry Rand Corp Horn antenna system
DE2031216A1 (en) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Day and date setting device for clocks with calendar
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
JP2004509617A (en) * 2000-09-08 2004-04-02 シェーリング　コーポレイション Mammalian genes; related reagents and methods
US11068393B2 (en) 2019-10-17 2021-07-20 Microsoft Technology Licensing, Llc Enhanced concurrency garbage collection stack scanning

Also Published As

Publication number Publication date
JP2004509617A (en) 2004-04-02
WO2002020569A3 (en) 2003-01-23
US20090155242A1 (en) 2009-06-18
US20020142292A1 (en) 2002-10-03
WO2002020569A2 (en) 2002-03-14
US20120164147A1 (en) 2012-06-28
EP1315743A2 (en) 2003-06-04
ATE549347T1 (en) 2012-03-15
US20100104576A1 (en) 2010-04-29
US20110165165A1 (en) 2011-07-07
CN1452633A (en) 2003-10-29
EP2298789A1 (en) 2011-03-23
EP1315743B1 (en) 2012-11-07
US20050186620A1 (en) 2005-08-25
US7696317B2 (en) 2010-04-13
EP2298789B1 (en) 2012-03-14
CA2419979A1 (en) 2002-03-14
US8148507B2 (en) 2012-04-03
US7893211B2 (en) 2011-02-22
US7060800B2 (en) 2006-06-13
US7427668B2 (en) 2008-09-23
US8426573B2 (en) 2013-04-23
MXPA03002049A (en) 2003-07-24
JP2009039124A (en) 2009-02-26

Similar Documents

Publication Publication Date Title
AU2001294541A1 (en) Mammalian genes; related reagents and methods
AU6135101A (en) Mammalian receptor proteins; related reagents and methods
ZA200604026B (en) IL-23 and its receptor ; related reagents and methods
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
CY1109093T1 (en) Mammalian Receptor Proteins, Related Reagents, and Related Methods
EP2305715A3 (en) Monoclonal antibody to osteoprotegerin binding protein
WO2001090151A3 (en) Human receptor proteins; related reagents and methods
WO2001036467A3 (en) Mammalian receptor proteins; related reagents and methods
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
NZ515382A (en) OX2 receptor homologs
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
WO2003022992A3 (en) Mammalian genes; related reagents
WO2000034335A3 (en) 'death domain' containing receptors
WO2002063009A3 (en) Lp mammalian proteins; related reagents
WO2001046419A3 (en) Mammalian prion proteins; related reagents and methods
CY1114280T1 (en) ANTI-COMPETITIVE ANTI-COMPETITIVE ANTI-COMPETITIVE COMPETITORS OR THEIR RELIGIONS